Trial intelligence / Profile preview

Risperidone for developmental stuttering in Persian adolescents

IRCT20240410061463N1Phase 2Completed

Sponsor
Babol University of Medical Sciences
Start
Jul 2024
Modality
Small Molecules
Countries
1
01

Overview

Phase 2 trial of risperidone in childhood-onset fluency disorder (COFD), sponsored by Babol University of Medical Sciences. Started Jul 2024; status: completed.

02

Drugs

risperidone
03

Conditions

childhood-onset fluency disorder (COFD)

Beyond the preview

Go deeper on IRCT20240410061463N1.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on IRCT20240410061463N1.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call